Ann: Phase 1/2 CHM CDH17 CAR-T GMP Manufacturing Complete, page-58

The general question for the 3 Hopper comps is:

If all the platforms are that great, and the data plus the excited scientists plus the FDA seem to support that claim, why isn't there at least one big player, investor or pharma, ( apart of RAD Lantheus ) who takes a punt that cost hardly anything but could make them Billions.

Regardless of Hopper, one would have pounced. Why ALA and not CHM with great data in GBM treatment and Blood Cancer treatment?

Compared to ALA, just having CDH17 already in the clinic and ALA still years away from getting to that stage with iNKT, CHM should be worth 150m as well.

There is only one other explanation: Me, Steini, holding.